Shares of Amarin Corp. PLC (NASDAQ:AMRN) rose 7.1% on Friday . The stock traded as high as $2.58 and last traded at $2.56, with a volume of 6,465,620 shares traded. The stock had previously closed at $2.39.

AMRN has been the topic of several recent research reports. Jefferies Group reissued a “buy” rating and set a $3.50 price objective on shares of Amarin Corp. PLC in a report on Thursday, July 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Amarin Corp. PLC in a research report on Monday, May 9th. Finally, Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th.

The company has a 50-day moving average of $2.19 and a 200-day moving average of $1.76. The company’s market capitalization is $488.77 million.

Amarin Corp. PLC (NASDAQ:AMRN) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. During the same quarter in the previous year, the firm earned ($0.16) EPS. The company earned $25.30 million during the quarter, compared to analyst estimates of $26.77 million. The business’s quarterly revenue was up 60.4% compared to the same quarter last year. Analysts forecast that Amarin Corp. PLC will post ($0.49) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Amarin Corp. PLC stock. OppenheimerFunds Inc. raised its stake in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned approximately 2.90% of Amarin Corp. PLC worth $10,061,000 as of its most recent SEC filing.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.